U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801236) titled 'Phase 1 Study of ACE-232 to Treat Patients with Metastatic Castration-Resistant Prostate Cancer' on Jan. 19.
Brief Summary: This is an open label, phase I, multi-center study in adult patients with metastatic castration resistant prostate cancer (mCRPC). The purpose of this study is to determine if the experimental treatment with CYP11A1 inhibitor, ACE-232 is safe, tolerable and has anti-cancer activity in treated patients.
Study Start Date: April 01, 2025
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer (Adenocarcinoma)
MCRPC (metastatic Castration-resistant Prostate Cancer)
Intervention:
DRUG: ACE-232 tablets
ACE-232 t...